BioPharma Today

The Health Care Reform Corner – From the editors of "The Pink Sheet"

The Health Care Reform Corner – From the editors of "The Pink Sheet"

What are policymakers and stakeholders in Washington saying and doing about health care reform? In this periodic BioPharma Today feature, the editors of "The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.

Read today's features....

Will FTC Challenge Product Switching In Obama Administration?

Full article reprinted from "The Pink Sheet" June 30, 2009

Lawyers are wary that the Federal Trade Commission may take a more aggressive stance toward pharmaceutical industry practices in the Obama administration. Read more...

Playing Catch-up: Mylan And Biocon To Team Up On Generic Biologics

Article preview from "The Pink Sheet" DAILY June 30, 2009

Strong growth prospects for the global generic biologics space over the next decade are bringing together the world's third-largest generic drug maker Mylan and India's Biocon. The two signed a comprehensive deal June 29, which will divide development and certain other costs to bring bio-generics to the market. Read on...

Translating Obama For FDA

Full article reprinted from The RPM Report June 30, 2009

Jesse Goodman, FDA's new chief scientist and acting deputy commissioner, is in a pivotal role in the new Administration, as the bridge between the career staff at FDA and the incoming political leadership. His keynote address at the Food & Drug Law Institute Annual meeting is a must read for anyone looking for signs of how the Obama agenda will affect FDA. Read on...

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009

Article preview from IN VIVO June 30, 2009

Highlights from the Q1 2009 review of pharmaceutical and biotechnology dealmaking: With 57 transactions raising $1.09 billion, financing activity for Q1 2009 showed a 137% increase over Q4 2008's total. The largest deal was an initial public offering--Bristol-Myers Squibb Co. sold off 15% of Mead Johnson Nutrition Co. for $684 million-the first since Bioheart Inc.'s February 2008 IPO. In M&A, Big Pharma mega-mergers was the big story as two major players--Wyeth and Schering-Plough--were scooped up by Pfizer Inc. and Merck & Co. Inc., respectively, in deals together valued at $109 billion, making up 96% of the Q1 M&A dollar volume. Read on...

The Asia Corner - From the Editors of PharmAsia News

The Asia Corner - From the Editors of PharmAsia News June 30, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.

Read today's features...

The Asia Corner - From the Editors of PharmAsia News June 30, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.

Read today's features...

With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg

Article preview from "The Pink Sheet" June 25, 2009

Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb. Read on...

The Health Care Reform Corner – From the editors of "The Pink Sheet"

The Health Care Reform Corner – From the editors of "The Pink Sheet" June 23, 2009

What are policymakers and stakeholders in Washington saying and doing about health care reform? In this periodic BioPharma Today feature, the editors of "The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.

Read today's feature...

Krystexxa: Big Expectations For An Orphan Market

Article preview from "The Pink Sheet" June 23, 2009

Savient's Krystexxa , an orphan drug candidate for treatment-failure gout, could bring in $600 million or more in worldwide sales by 2015, considerably bumping up the firm's potential value and making it pretty enough for picking as a potential acquisition candidate - or at the very least a collaboration partner. Read on...

FDA Chief of Staff Vacancy Lets Hamburg Shape Leadership Team

Article reprinted from "The Pink Sheet" DAILY June 23, 2009

FDA Chief of Staff Susan Winckler has resigned her post at the agency, allowing Commissioner Margaret Hamburg to further shape FDA under the new administration. Read on...